Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CRYZ | Q08257 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Hydroxycyclophosphamide SCHEMBL17737224 | 1.00 | NPSR1 (0.54) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| SCHEMBL17635575 | 0.83 | NPSR1 (0.50) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| SCHEMBL17899474 | 0.82 | NPSR1 (0.57) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Perfosfamide SCHEMBL4652 | 0.81 | NPSR1 (0.49) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Perfosfamide SCHEMBL1650261 | 0.81 | NPSR1 (0.49) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| SCHEMBL10412906 | 0.80 | NPSR1 (0.36) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| SCHEMBL17897696 | 0.78 | NPSR1 (0.49) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| SCHEMBL12451557 | 0.78 | NPSR1 (0.49) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| SCHEMBL10412920 | 0.78 | NPSR1 (0.53) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| SCHEMBL10909406 | 0.77 | NPSR1 (0.44) | NPSR1KDM4EALOX15MAPK1CRYZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 890 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735045-A2 | OXAZAPHOSPHORINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | La Life Products, LLC (US) | 2026-05-06 | — | — | EP | claimed |
| US-20250009900-A1 | OXAZAPHOSPHORINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | LA LIFE PRODUCTS, LLC (US) | 2025-01-09 | — | — | US | claimed |
| WO-2025006970-A2 | OXAZAPHOSPHORINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | LA LIFE PRODUCTS, LLC (US) | 2025-01-02 | — | — | WO | claimed |
| CN-107823720-B | Balloon surface coating | 德国凯德诺有限责任公司 | 2021-01-29 | — | — | CN | claimed |
| CN-107823721-B | Balloon surface coating | 德国凯德诺有限责任公司 | 2021-01-29 | — | — | CN | claimed |
| CN-107823719-B | Balloon surface coating | 德国凯德诺有限责任公司 | 2021-01-29 | — | — | CN | claimed |
| US-10745701-B2 | Methods of identifying and treating poor-prognosis cancers | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2020-08-18 | — | — | US | claimed |
| US-20190292548-A1 | Methods Of Identifying And Treating Poor-Prognosis Cancers | THE TRUSTEES OF PRINCETON UNIVERSITY | 2019-09-26 | — | — | US | claimed |
| EP-1718347-B1 | BIOCOMPATIBLE COATING, METHOD, AND USE OF MEDICAL SURFACES | HEMOTEQ AG (DE) | 2017-03-08 | — | — | EP | claimed |
| US-9320722-B2 | Regulators of aldehyde dehydrogenase ALDH3A1 and related therapeutic methods | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-04-26 | — | — | US | claimed |
| WO-2004043400-A2 | PEPTIDE DEFORMYLASE ACTIVATED PRODRUGS | CELMED ONCOLOGY (USA), INC. (CA) | 2004-05-27 | — | — | WO | claimed |
| WO-2004002401-A2 | CASPASE INHIBITORS FOR THE TREATMENT OF DISEASES AND CONDITIONS CAUSED BY EXPOSURE TO RADIONUCLIDES, BIOLOGICAL AGENTS, OR CHEMICAL AGENTS | CYTOVIA, INC. (US) | 2004-01-08 | — | — | WO | claimed |
| US-6652849-B2 | A vector expressed in obligate anaerobes for the production of an enzyme capable of converting a non toxic prodrug to a toxic chemotherapeutic agent. | THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY | 2003-11-25 | — | — | US | claimed |
| US-20020182229-A1 | Anaerobe targeted enzyme mediated prodrug therapy | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2002-12-05 | — | — | US | claimed |
| US-RE37410-E1 | THE CHEMOTHERAPEUTIC AGENT IS INCORPORATED INTO AN RELEASED FROM A SYNTHETIC POLYMERIC MATRIX BY DEGRADATION OF THE POLYMER MATRIX OR DIFFUSION OF THE AGENT OUT OF THE MATRIX OVER A PERIOD OF TIME OF AT LEAST EIGHT HOURS. | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2001-10-16 | — | — | US | claimed |
| US-5955100-A | TREATMENT OF MALIGNANT TUMORS, INFLAMMATORY DISEASES, OR AUTOIMMUNE DISEASES | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1999-09-21 | — | — | US | claimed |
| US-5733541-A | COCULTURED WITH OSTEOBLASTS | THE REGENT OF THE UNIVERSITY OF MICHIGAN (US) | 1998-03-31 | — | — | US | claimed |
| US-5621002-A | HAVING A MODIFIED COMPETITIVE ENZYME ACTIVITY INHBITOR LINKED TO A SPACER-DRUG; ENZYME CLEAVAGE AT A LOWER CONCENTRATION, I.E. LOW MICHAELIS-MENTEN CONSTANT(KM) | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1997-04-15 | — | — | US | claimed |
| EP-0647450-A1 | Improved prodrugs for enzyme mediated activation | BEHRINGWERKE Aktiengesellschaft (DE) | 1995-04-12 | — | — | EP | claimed |
| EP-0642799-A1 | Improved prodrugs for enzyme mediated activation | BEHRINGWERKE Aktiengesellschaft (DE) | 1995-03-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020182229-A1 | Anaerobe targeted enzyme mediated prodrug therapy | APRT, BLVRB, DPYD | NPSR1 3784/4885KDM4E 1237/4885ALOX15 850/4885 |
| US-20250009900-A1 | OXAZAPHOSPHORINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | ENTPD1, ENTPD2, ENTPD3 | NPSR1 3456/4885KDM4E 2708/4885ALOX15 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.